clifffiscal

Article Comment

clifffiscal commented on an article. 6:08 PM

Tackling Cancer: Bladder Cancer's Biggest Current & Upcoming Players

Sean. I don't think this part concerning how treatment is done using Provenge is accurate "then reinjects them back into a patient's prostate."

Article Comment

clifffiscal commented on an article. 7:50 PM

Vringo: the Good, the Bad, and the Lawsuit

The dilution you mentioned was done to raise money to pursue litigation on the IP that Vringo owns and is continuing with the additional results pending as mentioned above. In addition to those, will be suits against ZTE involving

[more]

Article Comment

clifffiscal commented on an article. 3:35 PM

Facebook's Next Revenue Idea Shines a Spotlight on Patent Problems

Any fifth grader could come up with the idea for search patents huh? Then why do I remember so many articles back in the 1990s that wondered about search engines and how great they were but when would they ever have real earnings.

[more]

Article Comment

clifffiscal commented on an article. 7:11 PM

Is Now the Time to Buy Vringo?

"Nitty-gritty details" are missing! How does one talk about VRNG and not mention the patent infringement suits with Google, Microsoft and ZTE?

Article Comment

clifffiscal commented on an article. 7:09 PM

Dendreon's Big Quarter: Key Takeaways

Another side of this story is new evidence showing benefits from sequencing with Xtandi and long-term (years) benefit from Provenge.

Article Comment

clifffiscal commented on an article. 12:06 PM

Dendreon Earnings: An Early Look

Doctors are just beginning to use Provenge at an earlier point in the disease and sequencing with other drugs is at an early point as well. There is very encouraging data emerging that the long-term effect with Provenge continues

[more]